Biotechnology - Mergers & Acquisitions, Research

Filter

Popular Filters

1 to 25 of 33 results

Roche invests in Stratos Genomics for “Sequencing by Expansion”

Roche invests in Stratos Genomics for “Sequencing by Expansion”

26-06-2014

Swiss pharma major Roche has made a strategic investment in USA-based Stratos Genomics and entered into…

BiotechnologyMergers & AcquisitionsResearchRocheStratos Genomics

NeoStem to acquire California Stem Cell, expanding pipeline

14-04-2014

USA-based NeoStem has entered into a definitive agreement to acquire California Stem Cell, an Irvine,…

BiotechnologyCalifornia Stem Cellmelapuldencel-TMergers & AcquisitionsNeoStemOncologyResearch

Second collaboration between FORMA Therapeutics and Celgene

02-04-2014

Privately-held drug discovery firm FORMA Therapeutics has entered a second strategic collaboration and…

BiotechnologyCelgeneFORMA TherapeuticsLicensingMergers & AcquisitionsResearch

Ohr Pharma and Cold Spring Harbor Lab set up JV to develop trodusquemine

03-03-2014

US biotech firm Ohr Pharmaceutical and not-for-profit cancer research center Cold Spring Harbor Laboratory…

BiotechnologyDepYmedMergers & AcquisitionsOhr PharmaceuticalResearchtrodusquemine

Genzyme to gain rights to certain Alnylam rare disease pipeline products

Genzyme to gain rights to certain Alnylam rare disease pipeline products

13-01-2014

French drug major Sanofi’s US biotech subsidiary Genzyme and Alnylam Pharmaceuticals have significantly…

Alnylam PharmaceuticalsBiotechnologyGenzymeLicensingMergers & AcquisitionspatisiranRare diseasesResearchSanofi

OncoMed rockets on possible multi-billion dollar deal with Celgene

OncoMed rockets on possible multi-billion dollar deal with Celgene

04-12-2013

US biotech companies OncoMed Pharmaceuticals and Celgene have entered an agreement to jointly develop…

Anti-DLL4BiotechnologyCelgenedemcizumabLicensingMergers & AcquisitionsOMP-21M18OncologyOncoMed PharmaceuticalsResearch

Merck KGaA eighth EPP spin-off to focus on infertility treatment

Merck KGaA eighth EPP spin-off to focus on infertility treatment

02-12-2013

USA-based EMD Serono, one of German drug and chemical group Merck KGaA’s biotechnology subsidiaries,…

BiotechnologyEMD SeronoMerck KGaAMerck SeronoMergers & AcquisitionsReproductiveResearchTocopheRx

Aphios spins off Amylon to develop novel Alzheimer’s disease drug

21-11-2013

US clinical-stage biotech firm Aphios says it has spun-off a subsidiary, Amylon, to finance, develop…

AmylonAPH-1104AphiosBiotechnologyFinancialMergers & AcquisitionsNeurologicalResearch

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

PharmAkea, Celgene and Bay City Capital collaborate on cancer and fibrotic disease

09-10-2013

PharmAkea Therapeutics and Bay City Capital have entered a strategic collaboration with Celgene designed…

BiotechnologyCelgeneMergers & AcquisitionsNorth AmericaOncologyPharmAkeaResearch

Biotech industry has "implementation gap" around demonstrating the value of products under development

07-05-2013

Ernst & Young's annual biotech report shows strong performance by major players but a challenging environment…

BiotechnologyEuropeFinancialMergers & AcquisitionsNorth AmericaResearch

Ligand acquires financial rights to over 15 development programs from Selexis

01-05-2013

US drugmaker Ligand Pharmaceuticals (Nasdaq: LGND) has acquired a portfolio of potential future milestone…

BiotechnologyLigand PharmaceuticalsMergers & AcquisitionsResearchSelexis

AstraZeneca acquires AlphaCore; Merck Serono links with BioMed X

03-04-2013

In line with its stated policy of targeted acquisitions, Anglo-Swedish drug major AstraZeneca (LSE: AZN)…

AlphaCore PharmaAstraZenecaBiotechnologyCardio-vascularMerck KGaAMerck SeronoMergers & AcquisitionsMetabolicsPharmaceuticalResearch

News briefs from Alimera on Iluvien and Xencor on Xtend; Galapagos milestone and acquisition

17-01-2013

US biopharma company Alimera Sciences (Nasdaq: ALIM) says that the Spanish Agency of Drugs and Medical…

Alimera SciencesBiotechnologyCangenixGalapagosIluvienJanssenJohnson & JohnsonMergers & AcquisitionsOphthalmicsPharmaceuticalRegulationResearchXencorXtend

Almirall expands in personalized medicine with 5% equity stake in AB-Biotics

24-10-2012

Spain's largest pharma company Almirall (ALM.MC) says it has reached an agreement with the Spanish biotech…

AB-BioticsAlmirallBiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Celgene in deal with PharmAria, including an acquisition option

16-10-2012

Recently-formed drug discovery company PharmAria has entered into an agreement with US biotech firm Celgene…

BiotechnologyCelgeneMergers & AcquisitionsOncologyPharmAriaResearch

Achillion Pharma moves up as a contender in the HCV market, GlobalData believes

02-10-2012

On September 27, Achillion Pharmaceuticals (Nasdaq: ACHN) released news of positive results surrounding…

ACH-3102Achillion PharmaceuticalsAnti-viralsBiotechnologyMergers & AcquisitionsPharmaceuticalResearch

Russia's Maxwell Biotech Venture Fund invests in Osteros Biomedica

26-09-2012

Earlier this month, the investment committee of Maxwell Biotech Venture Fund (MBVF), founded with the…

BiotechnologyMaxwell BiotechMBC PharmaMBC-11Mergers & AcquisitionsOncologyOsteros BiomedicaResearch

Compugen and Merck Serono set up biomarker company Neviah Genomics

25-06-2012

German drug major Merck KGaA's (MRK: DE) Merck Serono division and Israel-based Compugen (Nasdaq: CGEN)…

BiotechnologyCompugenMerck KGaAMerck SeronoMergers & AcquisitionsResearch

Pharming considers options, including a sale of the company

13-06-2012

Netherland-based biotech company Pharming Group (NYSE Euronext: PHARM) yesterday revealed that it is…

BiotechnologyLicensingMergers & AcquisitionsPharmingRare diseasesResearchRuconest

Sanofi's Aubagio reduces MS relapse; firm aims to build diabetes portfolio

01-06-2012

Genzyme, a subsidiary of French drug major Sanofi (Euronext: SAN) today reported top-line results from…

AubagioBiotechnologyDiabetesGenzymeMergers & AcquisitionsNeurologicalPharmaceuticalResearchSanofiteriflunomide

Empty pipelines drive deal valuations in pharmaceuticals sector, say IMAP

10-05-2012

A drought of domestic growth opportunities and new products is inflating valuations for R&D companies…

BiotechnologyMergers & AcquisitionsPharmaceuticalResearch

1 to 25 of 33 results

Company Spotlight

ImmunoGen

ImmunoGen

Back to top